Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 7
Submit an article Journal homepage
516
Views
20
CrossRef citations to date
0
Altmetric
Vaccine profile

Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine

Candice Yuen-Yue Chan Division of Infectious Diseases, Department of Medicine, 5 Lower Kent Ridge Road, Singapore 119074, Singapore
&
Paul Anantharajah Tambyah Division of Infectious Diseases, Department of Medicine, 5 Lower Kent Ridge Road, Singapore 119074, Singapore. [email protected]
Pages 759-773 | Published online: 09 Jan 2014

References

  • Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect. Dis. 4(8), 499–509 (2004).
  • Treanor JJ. Influenza viruses, including avian influenza and swine influenza. In: Manell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (7th Edition). Mandell GL, Bennett JE, Dolin R (Eds). Churchill Livingstone, PA, USA, 2265–2288 (2009).
  • Wang S, Le TQ, Kurihara N et al. Influenza virus–cytokine–protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J. Infect. Dis. 202(7), 991–1001 (2010).
  • Zimmer SM, Burke DS. Historical perspective – emergence of influenza A (H1N1) viruses. N. Engl. J. Med. 361(3), 279–285 (2009).
  • Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 442(7101), 448–452 (2006).
  • Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb. Mortal. Wkly Rep. 60, 1128–1132 (2011).
  • Wood JM, Williams MS. History of inactivated vaccines. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, Oxford, UK, 317–323 (1998).
  • Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16(9–10), 960–968 (1998).
  • Ehrlich HJ, Müller M, Fritsch S et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 200(7), 1113–1118 (2009).
  • Ehrlich HJ, Müller M, Oh HM et al.; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358(24), 2573–2584 (2008).
  • Pandey A, Singh N, Sambhara S, Mittal SK. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum. Vaccin. 6(2), 178–188 (2010).
  • Audsley JM, Tannock GA. Cell-based influenza vaccines: progress to date. Drugs 68(11), 1483–1491 (2008).
  • Engels EA. Cancer risk associated with receipt of vaccines contaminated with simian virus 40: epidemiologic research. Expert Rev. Vaccines 4(2), 197–206 (2005).
  • Engels EA, Viscidi RP, Galloway DA et al. Case–control study of simian virus 40 and non-Hodgkin lymphoma in the United States. J. Natl Cancer Inst. 96(18), 1368–1374 (2004).
  • Strickler HD, Rosenberg PS, Devesa SS, Hertel J, Fraumeni JF Jr, Goedert JJ. Contamination of poliovirus vaccines with simian virus 40 (1955–1963) and subsequent cancer rates. JAMA 279(4), 292–295 (1998).
  • Poulin DL, DeCaprio JA. Is there a role for SV40 in human cancer? J. Clin. Oncol. 24(26), 4356–4365 (2006).
  • Glezan WP. Cell-culture-derived influenza vaccine production. Lancet 377(9767), 698–700 (2011).
  • Pandey A, Singh N, Mittal SK. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum. Vaccin. doi:10.4161/hv.6.2.9899 (2010) (Epub ahead of print)
  • Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 160(2), 191–198 (1989).
  • Palache AM, Scheepers HS, de Regt V et al. Safety, reactogenicity and immunogenicity of Madin Darby canine kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev. Biol. Stand. 98, 115–125; discussion 133 (1999).
  • Percheson PB, Trépanier P, Dugré R, Mabrouk T. A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line. Dev. Biol. Stand. 98, 127–132; discussion 133 (1999).
  • Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1), S20–S23 (1997).
  • Halperin SA, Nestruck AC, Eastwood BJ. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine 16(13), 1331–1335 (1998).
  • Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 27(5), 786–791 (2009).
  • Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 27(43), 6022–6029 (2009).
  • Szymczakiewicz-Multanowska A, Groth N, Bugarini R et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis. 200(6), 841–848 (2009).
  • Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J. Infect. Dis. 200(6), 849–857 (2009).
  • Yasuda Y, Komatsu R, Matsushita K et al. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Adv. Ther. 27(7), 444–457 (2010).
  • Keitel W, Groth N, Lattanzi M et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a Phase 1/2 clinical trial. Vaccine 28(3), 840–848 (2010).
  • Frey S, Vesikari T, Szymczakiewicz-Multanowska A et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin. Infect. Dis. 51(9), 997–1004 (2010).
  • Kistner O, Howard MK, Spruth M et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25(32), 6028–6036 (2007).
  • Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months–12 years: open label, randomised, parallel group, multicentre study. BMJ 340, c2649 (2010).
  • Barrett PN, Berezuk G, Fritsch S et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 377(9767), 751–759 (2011).
  • Nicholson KG, Abrams KR, Batham S et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect. Dis. 11(2), 91–101 (2011).
  • Keitel WA, Dekker CL, Mink C et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 27(47), 6642–6648 (2009).
  • Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem. 389(5), 569–577 (2008).
  • Belongia EA, Kieke BA, Donahue JG et al.; Marshfield Influenza Study Group. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004–2005 season to the 2006–2007 season. J. Infect. Dis. 199(2), 159–167 (2009).
  • Beran J, Wertzova V, Honegr K et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect. Dis. 9, 2 (2009).
  • Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355(24), 2513–2522 (2006).
  • Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 7, CD001269 (2010).
  • Lagler H, Wenisch JM, Tobudic S et al. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination. Vaccine 29(40), 6888–6893 (2011).
  • Gregerson JP. A risk assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine 26(26), 3297–3304 (2008).
  • Cox RJ, Madhun AS, Hauge S et al. A Phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27(13), 1889–1897 (2009).
  • Centres for Disease Control and Prevention (CDC). Update: Influenza activity – United states and worldwide, 2003–04 season, and composition of the 2004–5 influenza vaccine. MMWR Morb. Mortal. Wkly Rep. 53(25), 547–552 (2004).
  • Centres for Disease Control and Prevention (CDC). Update: influenza activity – United states, 2010–11 season, and composition of the 2011–12 influenza vaccine. MMWR Morb. Mortal. Wkly Rep. 60(21), 705–712 (2011).
  • Minor PD, Engelhardt OG, Wood JM et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 27(22), 2907–2913 (2009).
  • George M, Farooq M, Dang T, Cortes B, Liu J, Maranga L. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol. Bioeng. 106(6), 906–917 (2010).
  • Stech J, Garn H, Herwig A et al. Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine. J. Infect. Dis. 204(10), 1483–1490 (2011).
  • Masic A, Babiuk LA, Zhou Y. Reverse genetics-generated elastase-dependent swine influenza viruses are attenuated in pigs. J. Gen. Virol. 90(Pt 2), 375–385 (2009).
  • Gabriel G, Garn H, Wegmann M et al. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine 26(7), 956–965 (2008).
  • Wressnigg N, Voss D, Wolff T et al. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine 27(21), 2851–2857 (2009).
  • Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. 2, CD004879 (2008).
  • Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev. 2, CD004876 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.